Cover
Cover - shares | 3 Months Ended | |
Apr. 01, 2022 | Apr. 26, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Apr. 1, 2022 | |
Document Transition Report | false | |
Entity File Number | 001-33072 | |
Entity Registrant Name | Leidos Holdings, Inc. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 20-3562868 | |
Entity Address, Address Line One | 1750 Presidents Street, | |
Entity Address, City or Town | Reston, | |
Entity Address, State or Province | VA | |
Entity Address, Postal Zip Code | 20190 | |
City Area Code | 571 | |
Local Phone Number | 526-6000 | |
Title of 12(b) Security | Common stock, par value $.0001 per share | |
Trading Symbol | LDOS | |
Security Exchange Name | NYSE | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 136,662,094 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q1 | |
Entity Central Index Key | 0001336920 | |
Current Fiscal Year End Date | --12-30 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions | Apr. 01, 2022 | Dec. 31, 2021 |
Assets: | ||
Cash and cash equivalents | $ 297 | $ 727 |
Receivables, net | 2,419 | 2,189 |
Inventory, net | 279 | 274 |
Other current assets | 492 | 429 |
Total current assets | 3,487 | 3,619 |
Property, plant and equipment, net | 674 | 670 |
Intangible assets, net | 1,109 | 1,177 |
Goodwill | 6,742 | 6,744 |
Operating lease right-of-use assets, net | 600 | 612 |
Other assets | 418 | 439 |
Total assets | 13,030 | 13,261 |
Liabilities: | ||
Accounts payable and accrued liabilities | 2,214 | 2,141 |
Accrued payroll and employee benefits | 724 | 605 |
Short-term debt and current portion of long-term debt | 556 | 483 |
Total current liabilities | 3,494 | 3,229 |
Long-term debt, net of current portion | 4,569 | 4,593 |
Operating lease liabilities | 582 | 589 |
Deferred tax liabilities | 182 | 239 |
Other long-term liabilities | 195 | 267 |
Total liabilities | 9,022 | 8,917 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Common stock, $0.0001 par value, 500 million shares authorized, 137 million and 140 million shares issued and outstanding at April 1, 2022, and December 31, 2021, respectively | 0 | 0 |
Additional paid-in capital | 1,928 | 2,423 |
Retained earnings | 2,007 | 1,880 |
Accumulated other comprehensive income (loss) | 20 | (12) |
Total Leidos stockholders’ equity | 3,955 | 4,291 |
Non-controlling interest | 53 | 53 |
Total stockholders' equity | 4,008 | 4,344 |
Total liabilities and stockholders' equity | $ 13,030 | $ 13,261 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares | Apr. 01, 2022 | Dec. 31, 2021 |
Stockholders’ equity: | ||
Common stock, par value (dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 500,000,000 | 500,000,000 |
Common stock, shares issued (in shares) | 137,000,000 | 140,000,000 |
Common stock, shares outstanding (in shares) | 137,000,000 | 140,000,000 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) $ in Millions | 3 Months Ended | |
Apr. 01, 2022 | Apr. 02, 2021 | |
Income Statement [Abstract] | ||
Revenues | $ 3,494 | $ 3,315 |
Cost of revenues | 2,982 | 2,848 |
Selling, general and administrative expenses | 236 | 159 |
Acquisition, integration and restructuring costs | 3 | 5 |
Equity loss (earnings) of non-consolidated subsidiaries | 2 | (5) |
Operating income | 271 | 308 |
Non-operating expense: | ||
Interest expense, net | (48) | (45) |
Other expense, net | (1) | (1) |
Income before income taxes | 222 | 262 |
Income tax expense | (45) | (57) |
Net income | 177 | 205 |
Less: net income attributable to non-controlling interest | 2 | 0 |
Net income attributable to Leidos common stockholders | $ 175 | $ 205 |
Earnings per share: | ||
Basic (dollars per share) | $ 1.26 | $ 1.44 |
Diluted (dollars per share) | $ 1.25 | $ 1.42 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions | 3 Months Ended | |
Apr. 01, 2022 | Apr. 02, 2021 | |
Statement of Comprehensive Income [Abstract] | ||
Net income | $ 177 | $ 205 |
Foreign currency translation adjustments | 2 | (4) |
Unrecognized gain on derivative instruments | 29 | 13 |
Pension adjustments | 1 | 0 |
Total other comprehensive income, net of taxes | 32 | 9 |
Comprehensive income | 209 | 214 |
Less: net income attributable to non-controlling interest | 2 | 0 |
Comprehensive income attributable to Leidos common stockholders | $ 207 | $ 214 |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) - USD ($) shares in Millions, $ in Millions | Total | Leidos Holdings, Inc. stockholders' equity | Shares of common stock | Additional paid-in capital | Retained earnings | Accumulated other comprehensive income | Non-controlling interest |
Beginning balance (in shares) at Jan. 01, 2021 | 142 | ||||||
Beginning Balance at Jan. 01, 2021 | $ 3,871 | $ 3,862 | $ 2,580 | $ 1,328 | $ (46) | $ 9 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net income | 205 | 205 | 205 | ||||
Other comprehensive income, net of taxes | 9 | 9 | 9 | ||||
Issuances of stock | 14 | 14 | 14 | ||||
Repurchases of stock and other (in shares) | (1) | ||||||
Repurchases of stock and other | (123) | (123) | (123) | ||||
Dividends | (49) | (49) | (49) | ||||
Stock-based compensation | 15 | 15 | 15 | ||||
Capital distributions to non-controlling interests | 38 | 38 | |||||
Ending balance (in shares) at Apr. 02, 2021 | 141 | ||||||
Ending Balance at Apr. 02, 2021 | 3,980 | 3,933 | 2,486 | 1,484 | (37) | 47 | |
Beginning balance (in shares) at Dec. 31, 2021 | 140 | ||||||
Beginning Balance at Dec. 31, 2021 | 4,344 | 4,291 | 2,423 | 1,880 | (12) | 53 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net income | 177 | 175 | 175 | 2 | |||
Other comprehensive income, net of taxes | 32 | 32 | 32 | ||||
Issuances of stock (shares) | 1 | ||||||
Issuances of stock | 15 | 15 | 15 | ||||
Repurchases of stock and other (in shares) | (4) | ||||||
Repurchases of stock and other | (526) | (526) | (526) | ||||
Dividends | (48) | (48) | (48) | ||||
Stock-based compensation | 16 | 16 | 16 | ||||
Capital distributions to non-controlling interests | (2) | (2) | |||||
Ending balance (in shares) at Apr. 01, 2022 | 137 | ||||||
Ending Balance at Apr. 01, 2022 | $ 4,008 | $ 3,955 | $ 1,928 | $ 2,007 | $ 20 | $ 53 |
CONDENSED CONSOLIDATED STATEM_4
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) (Parenthetical) - $ / shares | 3 Months Ended | |
Apr. 01, 2022 | Apr. 02, 2021 | |
Statement of Stockholders' Equity [Abstract] | ||
Dividends (dollars per share) | $ 0.36 | $ 0.34 |
CONDENSED CONSOLIDATED STATEM_5
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Millions | 3 Months Ended | |
Apr. 01, 2022 | Apr. 02, 2021 | |
Cash flows from operations: | ||
Net income | $ 177 | $ 205 |
Adjustments to reconcile net income to net cash provided by operations: | ||
Depreciation and amortization | 85 | 77 |
Stock-based compensation | 16 | 15 |
Deferred income taxes | (61) | 0 |
Other | 4 | (8) |
Change in assets and liabilities, net of effects of acquisitions: | ||
Receivables | (232) | (10) |
Other current assets and other long-term assets | (28) | 5 |
Accounts payable and accrued liabilities and other long-term liabilities | (60) | (148) |
Accrued payroll and employee benefits | 124 | 50 |
Income taxes receivable/payable | 68 | 53 |
Net cash provided by operating activities | 93 | 239 |
Cash flows from investing activities: | ||
Acquisition of businesses, net of cash acquired | (2) | (218) |
Divestiture of a business | 9 | 0 |
Payments for property, equipment and software | (28) | (26) |
Net cash used in investing activities | (21) | (244) |
Cash flows from financing activities: | ||
Net proceeds from commercial paper | 75 | 0 |
Payments of long-term debt | (27) | (26) |
Dividend payments | (51) | (50) |
Repurchases of stock and other | (526) | (123) |
Net capital (distribution to) contributions from non-controlling interests | (2) | 38 |
Proceeds from issuances of stock | 12 | 13 |
Net cash used in financing activities | (519) | (148) |
Net decrease in cash, cash equivalents and restricted cash | (447) | (153) |
Cash, cash equivalents and restricted cash at beginning of period | 875 | 687 |
Cash, cash equivalents and restricted cash at end of period | 428 | 534 |
Less: restricted cash at end of period | 131 | 157 |
Cash and cash equivalents at end of period | 297 | 377 |
Supplementary cash flow information: | ||
Cash paid for income taxes, net of refunds | 8 | 8 |
Cash paid for interest | 38 | 35 |
Property, plant and equipment additions | 2 | 0 |
Finance lease obligations | $ 0 | $ 45 |
Basis of Presentation and Summa
Basis of Presentation and Summary of Significant Accounting Policies | 3 Months Ended |
Apr. 01, 2022 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Summary of Significant Accounting Policies | Note 1–Basis of Presentation and Summary of Significant Accounting Policies Nature of Operations and Basis of Presentation Leidos Holdings, Inc. ("Leidos"), a Delaware corporation, is a holding company whose direct 100%-owned subsidiary and principal operating company is Leidos, Inc. Leidos is a FORTUNE 500 ® technology, engineering, and science company that provides services and solutions in the defense, intelligence, civil and health markets, both domestically and internationally. Leidos' customers include the U.S. Department of Defense ("DoD"), the U.S. Intelligence Community, the U.S. Department of Homeland Security, the Federal Aviation Administration, the Department of Veterans Affairs and many other U.S. civilian, state and local government agencies, foreign government agencies and commercial businesses. Unless indicated otherwise, references to "we," "us" and "our" refer collectively to Leidos Holdings, Inc. and its consolidated subsidiaries. We operate in three reportable segments: Defense Solutions, Civil and Health. Additionally, we separately present the unallocable costs associated with corporate functions as Corporate. We have a controlling interest in Mission Support Alliance, LLC ("MSA"), a joint venture with Centerra Group, LLC. We also have a controlling interest in Hanford Mission Integration Solutions, LLC ("HMIS"), the legal entity for the follow-on contract to MSA's contract and a joint venture with Centerra Group, LLC and Parsons Government Services, Inc. The financial results for MSA and HMIS are consolidated into our unaudited condensed consolidated financial statements. The unaudited condensed consolidated financial statements also include the balances of all voting interest entities in which Leidos has a controlling voting interest ("subsidiaries") and a variable interest entity ("VIE") in which Leidos is the primary beneficiary. The consolidated balances of the VIE are not material to the unaudited condensed consolidated financial statements for the periods presented. Intercompany accounts and transactions between consolidated companies have been eliminated in consolidation. The accompanying unaudited condensed financial information has been prepared in accordance with the rules of the U.S. Securities and Exchange Commission and accounting principles generally accepted in the United States of America ("GAAP"). Certain disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. Management evaluates these estimates and assumptions on an ongoing basis, including those relating to estimated profitability of long-term contracts, indirect billing rates, allowances for doubtful accounts, inventories, right-of-use assets and lease liabilities, fair value and impairment of intangible assets and goodwill, income taxes, stock-based compensation expense and contingencies. These estimates have been prepared by management on the basis of the most current and best available information; however, actual results could differ materially from those estimates. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, which consist of normal recurring adjustments, necessary for a fair presentation thereof. The results reported in these unaudited condensed consolidated financial statements are not necessarily indicative of the results that may be expected for the entire year. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report on Form 10-K filed on February 15, 2022. Accounting Standards Updates ("ASU") Adopted ASU 2021-08, Business Combinations (Topic 805) In October 2021, the FASB issued ASU 2021-08, which amends how contract assets and liabilities acquired in a business combination are measured. Current guidance requires contract assets and liabilities to be measured at fair value in accordance with ASC 805, Business Combinations. The amendments in this Update remove the requirement to measure contract assets and liabilities at fair value and instead require that they be recognized in accordance with ASC 606, Revenue from Contracts with Customers. The amendments in this Update are effective for public business entities for the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and must be applied prospectively. Early adoption is permitted. We adopted the requirements of ASU 2021-08 using the prospective method effective the first day of fiscal 2022. For business combinations occurring after adoption, we will measure contract assets and liabilities acquired in accordance with ASC 606. Accounting Standards Updates Issued But Not Yet Adopted ASU 2020-04 and ASU 2021-01, Reference Rate Reform (Topic 848) In March 2020, the FASB issued ASU 2020-04 which provides companies with optional expedients and exceptions to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. This update provides optional expedients for applying accounting guidance to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of the reference rate reform. The amendments in this update are effective for all entities as of March 2020 and can be adopted using a prospective approach no later than December 31, 2022. In January 2021, the FASB issued ASU 2021-01 which amends the scope of ASU 2020-04. The amendments in this update are elective and provide optional relief for entities with hedge accounting and contract modifications affected by the discounting transition through December 31, 2022. Under this relief, entities may continue to account for contract modifications as a continuation of the existing contract and the continuation of the hedge accounting arrangement. We are currently evaluating the impacts of reference rate reform. We currently use the one-month LIBOR for which the rate publication will cease in June 2023. Changes in Estimates on Contracts Changes in estimates related to contracts accounted for using the cost-to-cost method of accounting are recognized in the period in which such changes are made for the inception-to-date effect of the changes, with the exception of contracts acquired through a business combination, where the adjustment is made for the period commencing from the date of acquisition. Changes in estimates on contracts were as follows: Three Months Ended April 1, April 2, (in millions, except per share amounts) Favorable impact $ 41 $ 31 Unfavorable impact (26) (19) Net impact to income before income taxes $ 15 $ 12 Impact on diluted EPS attributable to Leidos common stockholders $ 0.08 $ 0.06 The impact on diluted earnings per share ("EPS") attributable to Leidos common stockholders is calculated using the statutory tax rate. Revenue Recognized from Prior Obligations Revenue recognized from performance obligations satisfied in previous periods was $14 million and $9 million for the three months ended April 1, 2022, and April 2, 2021, respectively. The changes primarily related to revisions of variable consideration including award and incentive fees, and revisions to estimates at completion resulting from changes in contract scope, mitigation of contract risks or true-ups of contract estimates at the end of contract performance. Cash and Cash Equivalents Our cash equivalents are primarily comprised of investments in several large institutional money market accounts, with original maturity of three months or less. At April 1, 2022, and December 31, 2021, $176 million and $138 million, respectively, of outstanding payments were included within "Cash and cash equivalents" and "Accounts payable and accrued liabilities" correspondingly on the condensed consolidated balance sheets. Restricted Cash We have restricted cash balances, primarily representing advances from customers that are restricted for use on certain expenditures related to that customer's contract and cash collected from the sale of accounts receivable but not yet remitted to the financial institution (see Note 9–Sale of Accounts Receivable). Restricted cash balances are included as "Other current assets" in the condensed consolidated balance sheets. Our restricted cash balances were $131 million and $148 million at April 1, 2022, and December 31, 2021, respectively. |
Revenues from Contracts with Cu
Revenues from Contracts with Customers | 3 Months Ended |
Apr. 01, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Revenues from Contracts with Customers | Note 2–Revenues from Contracts with Customers Remaining Performance Obligations Remaining performance obligations ("RPO") represent the expected value of exercised contracts, both funded and unfunded, less revenue recognized to date. Remaining performance obligations do not include unexercised option periods and future potential task orders expected to be awarded under indefinite delivery/indefinite quantity ("IDIQ") contracts, General Services Administration Schedule or other master agreement contract vehicles, with the exception of certain IDIQ contracts where task orders are not competitively awarded and separately priced but instead are used as a funding mechanism, and where there is a basis for estimating future revenues and funding on future anticipated task orders. As of April 1, 2022, we had $15.4 billion of RPO and expect to recognize approximately 55% and 73% over the next 12 months and 24 months, respectively, with the remainder to be recognized thereafter. Disaggregation of Revenues We disaggregate revenues by customer-type, contract-type and geographic location for each of our reportable segments. These categories represent how the nature, timing and uncertainty of revenues and cash flows are affected. Disaggregated revenues by customer-type were as follows: Three Months Ended April 1, 2022 Defense Solutions Civil Health Total (in millions) DoD and U.S. Intelligence Community $ 1,539 $ 20 $ 238 $ 1,797 Other government agencies (1) 222 613 385 1,220 Commercial and non-U.S. customers 287 147 27 461 Total $ 2,048 $ 780 $ 650 $ 3,478 Three Months Ended April 2, 2021 Defense Solutions Civil Health Total (in millions) DoD and U.S. Intelligence Community $ 1,407 $ 13 $ 158 $ 1,578 Other government agencies (1) 272 605 407 1,284 Commercial and non-U.S. customers 278 125 26 429 Total $ 1,957 $ 743 $ 591 $ 3,291 (1) Includes federal government agencies other than the DoD and U.S. Intelligence Community, as well as state and local government agencies. Disaggregated revenues by contract-type were as follows: Three Months Ended April 1, 2022 Defense Solutions Civil Health Total (in millions) Cost-reimbursement and fixed-price-incentive-fee $ 1,183 $ 408 $ 167 $ 1,758 Firm-fixed-price 618 255 417 1,290 Time-and-materials and fixed-price-level-of-effort 247 117 66 430 Total $ 2,048 $ 780 $ 650 $ 3,478 Three Months Ended April 2, 2021 Defense Solutions Civil Health Total (in millions) Cost-reimbursement and fixed-price-incentive-fee $ 1,163 $ 374 $ 99 $ 1,636 Firm-fixed-price 553 262 392 1,207 Time-and-materials and fixed-price-level-of-effort 241 107 100 448 Total $ 1,957 $ 743 $ 591 $ 3,291 Disaggregated revenues by geographic location were as follows: Three Months Ended April 1, 2022 Defense Solutions Civil Health Total (in millions) United States $ 1,810 $ 741 $ 650 $ 3,201 International 238 39 — 277 Total $ 2,048 $ 780 $ 650 $ 3,478 Three Months Ended April 2, 2021 Defense Solutions Civil Health Total (in millions) United States $ 1,713 $ 704 $ 591 $ 3,008 International 244 39 — 283 Total $ 1,957 $ 743 $ 591 $ 3,291 Revenues by customer-type, contract-type and geographic location exclude lease income of $16 million and $24 million for the three months ended April 1, 2022 and April 2, 2021, respectively. Contract Assets and Liabilities Performance obligations are satisfied either over time as work progresses or at a point in time. Firm-fixed-price contracts are typically billed to the customer using milestone payments while cost-reimbursable and time and materials contracts are typically billed to the customer on a monthly or bi-weekly basis as indicated by the negotiated billing terms and conditions of the contract. As a result, the timing of revenue recognition, customer billings and cash collections for each contract results in a net contract asset or liability at the end of each reporting period. Contract assets consist of unbilled receivables, which is the amount of revenue recognized that exceeds the amount billed to the customer, where right to payment is not solely subject to the passage of time. Unbilled receivables exclude amounts billable where the right to consideration is unconditional. Contract liabilities consist of deferred revenue, which represents cash advances received prior to performance for programs and billings in excess of revenue recognized. The components of contract assets and contract liabilities consisted of the following: Balance sheet line item April 1, December 31, (in millions) Contract assets - current: Unbilled receivables Receivables, net $ 1,078 $ 1,022 Contract liabilities - current: Deferred revenue (1) Accounts payable and accrued liabilities $ 382 $ 364 Contract liabilities - non-current: Deferred revenue (1) Other long-term liabilities $ 25 $ 24 (1) Certain contracts record revenue net of cost of revenues, and therefore, the respective deferred revenue balance will not fully convert to revenue. The increase in unbilled receivables was primarily due to revenue recognized on certain contracts partially offset by the timing of billings. Revenue recognized for the three months ended April 1, 2022, of $188 million was included as a contract liability at December 31, 2021. Revenue recognized for the three months ended April 2, 2021, of $144 million was included as a contract liability at January 1, 2021. |
Acquisitions, Divestitures, Goo
Acquisitions, Divestitures, Goodwill and Intangible Assets | 3 Months Ended |
Apr. 01, 2022 | |
Business Combinations [Abstract] | |
Acquisitions, Divestitures, Goodwill and Intangible Assets | Note 3–Acquisitions, Divestitures, Goodwill and Intangible Assets Business Acquisitions On May 7, 2021 (the "Purchase Date"), we completed the acquisition of Gibbs & Cox for purchase consideration of approximately $375 million, net of $1 million of cash acquired. Gibbs & Cox is an independent engineering and design firm specializing in naval architecture, marine engineering, management support and engineering consulting. As of April 1, 2022, we had completed the determination of fair values of the acquired assets and liabilities assumed. The final goodwill recognized of $276 million represents intellectual capital and the acquired assembled workforce, neither of which qualify for recognition as a separate intangible asset. All of the goodwill recognized is tax deductible. The following table summarizes the fair value of intangible assets acquired at the Purchase Date and the related weighted average amortization period: Weighted average amortization period Fair value (in years) (in millions) Programs 12 $ 89 For the three months ended April 1, 2022, $27 million of revenues related to the Gibbs & Cox acquisition were recognized within the Defense Solutions reportable segmen t. On September 21, 2021, we completed an immaterial strategic business acquisition for preliminary purchase consideration of approximately $36 million. In connection with the transaction, we recognized an $8 million program intangible asset and preliminary goodwill of $25 million. Aviation & Missile Solutions LLC ("AMS") Divestiture On November 22, 2021, we signed a definitive agreement within our Defense Solutions segment to dispose of its AMS business in order to focus on leading-edge and technologically advanced services, solutions and products. The net sales price is $15 million, and the divestiture was completed on April 29, 2022. Goodwill The following table presents changes in the carrying amount of goodwill by reportable segment: Defense Solutions Civil Health Total (in millions) Goodwill at January 1, 2021 $ 3,300 $ 2,047 $ 966 $ 6,313 Acquisitions of businesses 425 5 — 430 Divestiture of a business (1) — — (1) Goodwill re-allocation (17) 17 — — Foreign currency translation adjustments (26) 28 — 2 Goodwill at December 31, 2021 $ 3,681 $ 2,097 $ 966 $ 6,744 Acquisition of a business 1 — — 1 Divestiture of a business (4) — — (4) Foreign currency translation adjustments 8 (7) — 1 Goodwill at April 1, 2022 $ 3,686 $ 2,090 $ 966 $ 6,742 As previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021, the estimated fair value of the Security Products reporting unit within the Civil reportable segment exceeded the carrying value by approximately 6% as of the most recent assessment date. In the event that there are significant unfavorable changes to the forecasted cash flows of the reporting unit (including if the impact of COVID-19 on passenger travel levels is more prolonged or severe than what is incorporated into our forecast), terminal growth rates or the cost of capital used in the fair value estimates, we may be required to record a material impairment of goodwill at a future date. During the three months ended April 1, 2022, and April 2, 2021, there were no impairments to goodwill. Intangible Assets Intangible assets, net consisted of the following: April 1, 2022 December 31, 2021 Gross carrying value Accumulated amortization Net carrying value Gross carrying value Accumulated amortization Net carrying value (in millions) Finite-lived intangible assets: Programs $ 1,701 $ (866) $ 835 $ 1,722 $ (830) $ 892 Software and technology 230 (127) 103 230 (121) 109 Customer relationships 91 (16) 75 97 (18) 79 Backlog 6 (6) — 38 (37) 1 Trade names 1 (1) — 1 (1) — Total finite-lived intangible assets 2,029 (1,016) 1,013 2,088 (1,007) 1,081 Indefinite-lived intangible assets: In-process research and development 92 — 92 92 — 92 Trade names 4 — 4 4 — 4 Total indefinite-lived intangible assets 96 — 96 96 — 96 Total intangible assets $ 2,125 $ (1,016) $ 1,109 $ 2,184 $ (1,007) $ 1,177 Amortization expense was $59 million and $55 million for the three months ended April 1, 2022 and April 2, 2021, respectively. Program intangible assets are amortized over their respective estimated useful lives in proportion to the pattern of economic benefit based on expected future discounted cash flows. Backlog and trade name intangible assets are amortized on a straight-line basis over their estimated useful lives. Customer relationships and software and technology intangible assets are amortized either on a straight-line basis over their estimated useful lives or over their respective estimated useful lives in proportion to the pattern of economic benefit based on expected future discounted cash flows, as deemed appropriate. The estimated annual amortization expense as of April 1, 2022, was as follows: Fiscal year ending (in millions) 2022 (remainder of year) $ 173 2023 203 2024 150 2025 120 2026 96 2027 and thereafter 271 $ 1,013 |
Fair Value Measurements
Fair Value Measurements | 3 Months Ended |
Apr. 01, 2022 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Note 4–Fair Value Measurements The accounting standard for fair value measurements establishes a three-level fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: observable inputs such as quoted prices in active markets (Level 1); inputs other than quoted prices in active markets that are observable, either directly or indirectly, or quoted prices that are not active (Level 2); and unobservable inputs in which there is little or no market data (e.g., discounted cash flow and other similar pricing models), which requires us to develop our own assumptions about the assumptions that market participants would use in pricing the asset or liability (Level 3). The financial instruments measured at fair value on a recurring basis primarily consisted of the following: April 1, 2022 December 31, 2021 Carrying value Fair value Carrying value Fair value (in millions) Financial liabilities: Derivatives $ 13 $ 13 $ 53 $ 53 As of April 1, 2022, our derivatives primarily consisted of the cash flow interest rate swaps on $1.0 billion of the variable rate senior unsecured term loan (see "Note 5–Derivative Instruments"). The fair value of the cash flow interest rate swaps is determined based on observed values for underlying interest rates on the LIBOR yield curve and the underlying interest rate (Level 2 inputs). The carrying amounts of our financial instruments, other than derivatives, which include cash equivalents, accounts receivable, accounts payable and accrued expenses, are reasonable estimates of their related fair values. As of April 1, 2022, and December 31, 2021, the fair value of debt was $5.1 billion and $5.4 billion, respectively, and the carrying amount was $5.1 billion and $5.1 billion, respectively (see "Note 6–Debt"). The fair value of long-term debt is determined based on current interest rates available for debt with terms and maturities similar to our existing debt arrangements (Level 2 inputs). On May 7, 2021, and January 14, 2021, non-financial instruments measured at fair value on a non-recurring basis were recorded in connection with the acquisitions of Gibbs & Cox and 1901 Group. The fair values of the assets acquired and liabilities assumed were determined using Level 3 inputs. As of April 1, 2022, we did not have any assets or liabilities measured at fair value on a non-recurring basis. |
Derivative Instruments
Derivative Instruments | 3 Months Ended |
Apr. 01, 2022 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Instruments | Note 5–Derivative Instruments We manage our risk to changes in interest rates through the use of derivative instruments. We do not hold derivative instruments for trading or speculative purposes. For variable rate borrowings, we use fixed interest rate swaps, effectively converting a portion of the variable interest rate payments to fixed interest rate payments. These swaps are designated as cash flow hedges. The fair value of the interest rate swaps was as follows: Liability derivatives Balance sheet line item April 1, December 31, (in millions) Cash flow interest rate swaps Other long-term liabilities $ 13 $ 53 The cash flows associated with the interest rate swaps are classified as operating activities in the condensed consolidated statements of cash flows. Cash Flow Hedges We have interest rate swap agreements to hedge the cash flows of $1.0 billion of the variable rate senior unsecured term loan (the "Variable Rate Loan"). These interest rate swap agreements have a maturity date of August 2025 and a fixed interest rate of 3.00%. The objective of these instruments is to reduce variability in the forecasted interest payments of the Variable Rate Loan, which are based on the LIBOR rate. Under the terms of the interest rate swap agreements, we will receive monthly variable interest payments based on the one-month LIBOR rate and will pay interest at a fixed rate. The interest rate swap transactions were accounted for as cash flow hedges. The gain/loss on the swaps is reported as a component of other comprehensive income (loss) and is reclassified into earnings when the interest payments on the underlying hedged items impact earnings. A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective. The effect of the cash flow hedges on other comprehensive income (loss) and earnings for the periods presented was as follows: Three Months Ended April 1, April 2, (in millions) Total interest expense, net presented in the condensed consolidated statements of income in which the effects of cash flow hedges are recorded $ 48 $ 45 Amount recognized in other comprehensive income $ 32 $ 12 Amount reclassified from accumulated other comprehensive income (loss) to interest expense, net $ 6 $ 5 We expect to reclassify net losses of $15 million from accumulated other comprehensive income into earnings during the next 12 months. |
Debt
Debt | 3 Months Ended |
Apr. 01, 2022 | |
Debt Disclosure [Abstract] | |
Debt | Note 6–Debt Our debt consisted of the following: Stated interest rate Effective interest rate April 1, 2022 (1) December 31, 2021 (1) (in millions) Short-term debt: Commercial paper 0.52%-1.13% Various $ 75 $ — Senior unsecured term loans: $380 million term loan, due May 2022 1.59% 1.69% 380 380 Total short-term debt $ 455 $ 380 Long-term debt: Senior unsecured term loans: $1,925 million term loan, due January 2025 1.84% 2.11% $ 1,275 $ 1,298 Senior unsecured notes: $500 million notes, due May 2023 2.95% 3.17% 499 498 $500 million notes, due May 2025 3.63% 3.76% 497 497 $750 million notes due May 2030 4.38% 4.50% 738 738 $1,000 million notes, due February 2031 2.30% 2.38% 990 990 $250 million notes, due July 2032 7.13% 7.43% 247 247 $300 million notes, due July 2033 5.50% 5.88% 158 158 $300 million notes, due December 2040 5.95% 6.03% 216 216 Notes payable and finance leases due on various dates through fiscal 2032 1.56%-4.18% Various 50 54 Total long-term debt 4,670 4,696 Less current portion (101) (103) Total long-term debt, net of current portion $ 4,569 $ 4,593 (1) The carrying amounts of the senior unsecured term loans and notes as of April 1, 2022, and December 31, 2021, include the remaining principal outstanding of $5,041 million and $5,065 million, respectively, less total unamortized debt discounts and deferred debt issuances costs of $41 million and $43 million, respectively. Term Loans and Revolving Credit Facility We have a Credit Agreement (the "Credit Agreement") with certain financial institutions, which provided for a senior unsecured term loan facility in an aggregate principal amount of $1.9 billion (the "Term Loan Facility") and a $750 million senior unsecured revolving facility (the "Revolving Facility" and, together with the Term Loan Facility, the "Credit Facilities"). The Credit Facilities will mature in January 2025. The Revolving Facility permits two additional one-year extensions subject to lender consent. Borrowings under the Credit Agreement bear interest at a rate determined, at our option, based on either an alternate base rate or a LIBOR rate plus, in each case, an applicable margin that varies depending on our credit rating. The applicable margin range for LIBOR-denominated borrowings is from 1.13% to 1.75%. Based on our current ratings, the applicable margin for LIBOR-denominated borrowings is 1.38%. The financial covenants in the Credit Agreement require that we maintain, as of the last day of each fiscal quarter, a ratio of adjusted consolidated total debt to consolidated EBITDA of not more than 3.75 to 1.00, subject to two increases to 4.50 to 1.00 following a material acquisition, and a ratio of EBITDA to consolidated interest expense of not less than 3.50 to 1.00. On May 7, 2021, we entered into a Credit Agreement (the "2021 Credit Agreement") with certain financial institutions, which provided for a senior unsecured term loan facility in an aggregate principal amount of $380 million with maturity 364 days after the 2021 Credit Agreement date. The proceeds were used to fund the acquisition of Gibbs & Cox. Borrowings under the 2021 Credit Agreement bear interest at a rate determined, at our option, based on either an alternate base rate plus 0.13% or a LIBOR rate plus 1.13%. The financial covenants in the 2021 Credit Agreement require that we maintain, as of the last day of each fiscal quarter, a ratio of adjusted consolidated total debt to consolidated EBITDA of not more than 3.75 to 1.00, subject to increases to 4.50 to 1.00 following a material acquisition, and a ratio of EBITDA to consolidated interest expense of not less than 3.50 to 1.00. Commercial Paper We have a commercial paper program in which the Company may issue short-term unsecured commercial paper notes ("Commercial Paper Notes") not to exceed $750 million. The proceeds will be used for general corporate purposes, including working capital, capital expenditures, acquisitions and share repurchases. The Commercial Paper Notes are issued in minimum denominations of $0.25 million and have maturities of up to 397 days from the date of issuance. The Commercial Paper Notes either bear a stated or floating interest rate, if interest bearing, or will be sold at a discount from the face amount. As of April 1, 2022, we had $75 million of Commercial Paper Notes outstanding. Principal Payments and Debt Issuance Costs We made principal payments on our long-term debt of $27 million and $26 million during the three months ended April 1, 2022, and April 2, 2021, respectively. This activity included required principal payments on our term loans of $24 million for both the three months ended April 1, 2022, and April 2, 2021. As of April 1, 2022, and December 31, 2021, there were no borrowings outstanding under the Revolving Facility. Amortization of debt discount and debt issuance costs was $3 million and $2 million for the three months ended April 1, 2022, and April 2, 2021, respectively. The Credit Facilities, the 2021 Credit Agreement, Commercial Paper Notes, senior unsecured term loans and notes are fully and unconditionally guaranteed and contain certain customary restrictive covenants, including among other things, restrictions on our ability to create liens and enter into sale and leaseback transactions under certain circumstances. We were in compliance with all covenants as of April 1, 2022. |
Accumulated Other Comprehensive
Accumulated Other Comprehensive Income (Loss) | 3 Months Ended |
Apr. 01, 2022 | |
Equity [Abstract] | |
Accumulated Other Comprehensive Income (Loss) | Note 7–Accumulated Other Comprehensive Income (Loss) Changes in the components of accumulated other comprehensive income (loss) were as follows: Foreign currency translation adjustments Unrecognized gain (loss) on derivative instruments Pension adjustments Total accumulated other comprehensive income (loss) (in millions) Balance at January 1, 2021 $ 30 $ (70) $ (6) $ (46) Other comprehensive income (loss) (3) 18 17 32 Taxes (5) (8) (4) (17) Reclassification from accumulated other comprehensive income (loss) — 19 — 19 Balance at December 31, 2021 22 (41) 7 (12) Other comprehensive income (loss) (2) 32 1 31 Taxes 4 (9) — (5) Reclassification from accumulated other comprehensive income (loss) — 6 — 6 Balance at April 1, 2022 $ 24 $ (12) $ 8 $ 20 Reclassifications from unrecognized loss on derivative instruments are recorded in "Interest expense, net" in the condensed consolidated statements of income. |
Earnings Per Share
Earnings Per Share | 3 Months Ended |
Apr. 01, 2022 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | Note 8–Earnings Per Share The following table provides a reconciliation of the weighted average number of shares outstanding used to compute basic and diluted EPS for the periods presented: Three Months Ended April 1, April 2, (in millions) Basic weighted average number of shares outstanding 139 142 Dilutive common share equivalents—stock options and other stock awards 1 2 Diluted weighted average number of shares outstanding 140 144 Anti-dilutive stock-based awards are excluded from the weighted average number of shares outstanding used to compute diluted EPS. The total outstanding stock options and vesting stock awards that were anti-dilutive were 1 million for both the three months ended April 1, 2022, and April 2, 2021. On February 16, 2022, we entered into an Accelerated Share Repurchase ("ASR") agreement with a financial institution to repurchase shares of our outstanding common stock. We paid $500 million to the financial institution and received an initial delivery of 4.5 million shares at an average price of $88.72 per share. The purchase was recorded to "Additional paid-in capital" in the condensed consolidated balance sheets. All shares delivered were immediately retired. The specific number of shares that we will ultimately receive under the ASR agreement will be based on the volume-weighted-average-price during the period February 17, 2022, to May 16, 2022. |
Sale of Accounts Receivable
Sale of Accounts Receivable | 3 Months Ended |
Apr. 01, 2022 | |
Receivables [Abstract] | |
Sale of Accounts Receivable | Note 9–Sale of Accounts Receivable We have entered into purchase agreements with a financial institution which provide us the election to sell accounts receivable at a discount. The receivables sold are typically collectable from our customers within 30 days of the sale date. During the three months ended April 1, 2022, and April 2, 2021, we sold $209 million and $465 million, respectively, of accounts receivable under the agreements and received proceeds of $209 million and $464 million, respectively, which were classified as operating activities in the condensed consolidated statements of cash flows. These transfers have been recognized as a sale, as the receivables have been legally isolated from Leidos, the financial institution has the right to pledge or exchange the assets received and we do not maintain effective control over the transferred accounts receivable. Our only continuing involvement with the transferred financial assets is as the collection and servicing agent. As a result, the accounts receivable balance on the condensed consolidated balance sheets is presented net of the transferred amounts. No servicing asset or liability was recognized for continued servicing of the sold receivables, as the servicing fee approximates fair value. The difference between the carrying amount of the receivables sold and the net cash received was recognized as a loss on sale and was recorded within "Selling, general and administrative expenses" on the condensed consolidated statements of income. Sold receivables activity for the periods presented was as follows: Three Months Ended April 1, April 2, (in millions) Sales of accounts receivable $ 209 $ 465 Cash collections on sold receivables remitted to financial institution (209) (371) Outstanding balance sold to financial institution — 94 Cash collected but not yet remitted to financial institution — (19) Sold receivables due from customers $ — $ 75 |
Business Segments
Business Segments | 3 Months Ended |
Apr. 01, 2022 | |
Segment Reporting [Abstract] | |
Business Segments | Note 10–Business Segments Our operations and reportable segments are organized around the customers and markets we serve. We define our reportable segments based on the way the chief operating decision maker ("CODM"), currently our Chairman and Chief Executive Officer, manages operations for the purposes of allocating resources and assessing performance. The segment information for the periods presented was as follows: Three Months Ended April 1, April 2, (in millions) Revenues: Defense Solutions $ 2,049 $ 1,958 Civil 795 766 Health 650 591 Total revenues $ 3,494 $ 3,315 Operating income (loss): Defense Solutions $ 133 $ 152 Civil 43 74 Health 118 102 Corporate (23) (20) Total operating income $ 271 $ 308 The income statement performance measures used to evaluate segment performance are revenues and operating income. As a result, "Interest expense, net," "Other expense, net" and "Income tax expense" as reported in the condensed consolidated statements of income are not allocated to our segments. Under U.S. Government Cost Accounting Standards, indirect costs including depreciation expense are collected in indirect cost pools, which are then collectively allocated to the reportable segments based on a representative causal or beneficial relationship of the costs in the pool to the costs in the base. As such, depreciation expense is not separately disclosed on the condensed consolidated statements of income. |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Apr. 01, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Note 11–Commitments and Contingencies Contingencies VirnetX, Inc. ("VirnetX") On April 10, 2018, a jury trial concluded in an additional patent infringement case brought by VirnetX against Apple, referred to as the Apple II case, in which the jury returned a verdict against Apple for infringement and awarded VirnetX damages in the amount of over $502 million. On April 11, 2018, in a second phase of the Apple II trial, the jury found Apple's infringement to be willful. On August 30, 2018, the federal trial court in the Eastern District of Texas entered a final judgment and rulings on post-trial motions in the Apple II case. The court affirmed the jury’s verdict of over $502 million and granted VirnetX’s motions for supplemental damages, a sunset royalty and royalty rate of $1.20 per infringing device, along with pre-judgment and post-judgment interest and costs. The court denied VirnetX’s motions for enhanced damages, attorneys’ fees and an injunction. The court also denied Apple’s motions for judgment as a matter of law and for a new trial. An additional sum of over $93 million for costs and pre-judgment interest was subsequently agreed upon pursuant to a court order, bringing the total award to VirnetX in the Apple II case to over $595 million. Apple filed an appeal of the judgment in the Apple II case with the U.S. Court of Appeals for the Federal Circuit, and on November 22, 2019, the Federal Circuit affirmed in part, reversed in part and remanded the Apple II case back to the District Court. The Federal Circuit affirmed that Apple infringed two of the patents at issue in the case, and ruled that Apple is precluded from making certain patent invalidity arguments. However, the Federal Circuit reversed the judgment that Apple infringed two other patents at issue, vacated the prior damages awarded in the Apple II case, and remanded the Apple II case back to the District Court for further proceedings regarding damages. On April 23, 2020, the District Court ordered a new trial on damages in the Apple II case, which was delayed by the coronavirus pandemic and started on October 26, 2020. On October 30, 2020, the jury awarded VirnetX $503 million in damages and specified a royalty rate of $0.84 per infringing device. In January 2021, the District Court entered final judgment affirming the jury award and the parties separately agreed on additional costs and interest of over $75 million, subject to Apple's appeal. On February 4, 2021, Apple filed a notice of appeal with the U.S. Court of Appeals for the Federal Circuit in the Apple II case. Under our agreements with VirnetX, Leidos would receive 25% of the proceeds obtained by VirnetX after reduction for attorneys' fees and costs. However, the verdict in the Apple II case remains subject to the ongoing and potential future proceedings and appeals. In addition, the patents at issue in these cases are subject to U.S. Patent and Trademark Office post-grant inter partes review and/or reexamination proceedings and related appeals, which may result in all or part of these patents being invalidated or the claims of the patents being limited. Thus, no assurances can be given when or if we will receive any proceeds in connection with these jury awards. In addition, if Leidos receives any proceeds, we are required to pay a royalty to the customer who paid for the development of the technology. Government Investigations and Reviews We are routinely subject to investigations and reviews relating to compliance with various laws and regulations with respect to our role as a contractor to federal, state and local government customers and in connection with performing services in countries outside of the United States. Adverse findings could have a material effect on our business, financial position, results of operations and cash flows due to our reliance on government contracts. As of April 1, 2022, active indirect cost audits by the Defense Contract Audit Agency remain open for fiscal 2016 and subsequent fiscal years. Although we have recorded contract revenues based upon an estimate of costs that we believe will be approved upon final audit or review, we cannot predict the outcome of any ongoing or future audits or reviews and adjustments, and if future adjustments exceed estimates, our profitability may be adversely affected. As of April 1, 2022, we believe we have adequately reserved for potential adjustments from audits or reviews of contract costs. Through its internal processes, the Company discovered, in late 2021, activities by its employees, third party representatives and subcontractors, raising concerns related to a portion of our business that conducts international operations. The Company is conducting an internal investigation, overseen by an independent committee of the Board of Directors, with the assistance of external legal counsel, to determine whether the identified conduct may have violated the Company’s Code of Conduct and potentially applicable laws, including the U.S. Foreign Corrupt Practices Act ("FCPA"). The Company has voluntarily self-reported this investigation to the Department of Justice and the Securities and Exchange Commission and is cooperating with both agencies. Because the investigation is ongoing, the Company cannot anticipate the timing, outcome or possible impact of the investigation, although violations of the FCPA and other applicable laws may result in criminal and civil sanctions, including monetary penalties, and reputational damage. Commitments We have outstanding letters of credit of $51 million as of April 1, 2022, principally related to performance guarantees on contracts. We also have outstanding surety bonds with a notional amount of $100 million, principally related to performance and subcontractor payment bonds on contracts. The value of the surety bonds may vary due to changes in the underlying project status and/or contractual modifications. As of April 1, 2022, the future expirations of the outstanding letters of credit and surety bonds were as follows: Fiscal year ending (in millions) 2022 (remainder of year) $ 38 2023 11 2024 81 2025 5 2026 2 2027 and thereafter 14 $ 151 |
Basis of Presentation and Sum_2
Basis of Presentation and Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Apr. 01, 2022 | |
Accounting Policies [Abstract] | |
Consolidation | We have a controlling interest in Mission Support Alliance, LLC ("MSA"), a joint venture with Centerra Group, LLC. We also have a controlling interest in Hanford Mission Integration Solutions, LLC ("HMIS"), the legal entity for the follow-on contract to MSA's contract and a joint venture with Centerra Group, LLC and Parsons Government Services, Inc. The financial results for MSA and HMIS are consolidated into our unaudited condensed consolidated financial statements. The unaudited condensed consolidated financial statements also include the balances of all voting interest entities in which Leidos has a controlling voting interest ("subsidiaries") and a variable interest entity ("VIE") in which Leidos is the primary beneficiary. The consolidated balances of the VIE are not material to the unaudited condensed consolidated financial statements for the periods presented. Intercompany accounts and transactions between consolidated companies have been eliminated in consolidation. |
Basis of Accounting | The accompanying unaudited condensed financial information has been prepared in accordance with the rules of the U.S. Securities and Exchange Commission and accounting principles generally accepted in the United States of America ("GAAP"). Certain disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules. |
Estimates | The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. Management evaluates these estimates and assumptions on an ongoing basis, including those relating to estimated profitability of long-term contracts, indirect billing rates, allowances for doubtful accounts, inventories, right-of-use assets and lease liabilities, fair value and impairment of intangible assets and goodwill, income taxes, stock-based compensation expense and contingencies. These estimates have been prepared by management on the basis of the most current and best available information; however, actual results could differ materially from those estimates. |
Accounting Standards Updates ("ASU") Adopted and Updates Issued But Not Yet Adopted | Accounting Standards Updates ("ASU") Adopted ASU 2021-08, Business Combinations (Topic 805) In October 2021, the FASB issued ASU 2021-08, which amends how contract assets and liabilities acquired in a business combination are measured. Current guidance requires contract assets and liabilities to be measured at fair value in accordance with ASC 805, Business Combinations. The amendments in this Update remove the requirement to measure contract assets and liabilities at fair value and instead require that they be recognized in accordance with ASC 606, Revenue from Contracts with Customers. The amendments in this Update are effective for public business entities for the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and must be applied prospectively. Early adoption is permitted. We adopted the requirements of ASU 2021-08 using the prospective method effective the first day of fiscal 2022. For business combinations occurring after adoption, we will measure contract assets and liabilities acquired in accordance with ASC 606. Accounting Standards Updates Issued But Not Yet Adopted ASU 2020-04 and ASU 2021-01, Reference Rate Reform (Topic 848) In March 2020, the FASB issued ASU 2020-04 which provides companies with optional expedients and exceptions to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. This update provides optional expedients for applying accounting guidance to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of the reference rate reform. The amendments in this update are effective for all entities as of March 2020 and can be adopted using a prospective approach no later than December 31, 2022. In January 2021, the FASB issued ASU 2021-01 which amends the scope of ASU 2020-04. The amendments in this update are elective and provide optional relief for entities with hedge accounting and contract modifications affected by the discounting transition through December 31, 2022. Under this relief, entities may continue to account for contract modifications as a continuation of the existing contract and the continuation of the hedge accounting arrangement. We are currently evaluating the impacts of reference rate reform. We currently use the one-month LIBOR for which the rate publication will cease in June 2023. |
Changes in Estimates on Contracts | Changes in estimates related to contracts accounted for using the cost-to-cost method of accounting are recognized in the period in which such changes are made for the inception-to-date effect of the changes, with the exception of contracts acquired through a business combination, where the adjustment is made for the period commencing from the date of acquisition.The impact on diluted earnings per share ("EPS") attributable to Leidos common stockholders is calculated using the statutory tax rate.The changes primarily related to revisions of variable consideration including award and incentive fees, and revisions to estimates at completion resulting from changes in contract scope, mitigation of contract risks or true-ups of contract estimates at the end of contract performance. |
Cash and Cash Equivalents | Our cash equivalents are primarily comprised of investments in several large institutional money market accounts, with original maturity of three months or less.outstanding payments were included within "Cash and cash equivalents" and "Accounts payable and accrued liabilities" correspondingly on the condensed consolidated balance sheets. |
Restricted Cash | We have restricted cash balances, primarily representing advances from customers that are restricted for use on certain expenditures related to that customer's contract and cash collected from the sale of accounts receivable butnot yet remitted to the financial institution (see Note 9–Sale of Accounts Receivable). Restricted cash balances are included as "Other current assets" in the condensed consolidated balance sheets. |
Basis of Presentation and Sum_3
Basis of Presentation and Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Apr. 01, 2022 | |
Accounting Policies [Abstract] | |
Schedule of changes In estimates on contracts | Changes in estimates on contracts were as follows: Three Months Ended April 1, April 2, (in millions, except per share amounts) Favorable impact $ 41 $ 31 Unfavorable impact (26) (19) Net impact to income before income taxes $ 15 $ 12 Impact on diluted EPS attributable to Leidos common stockholders $ 0.08 $ 0.06 |
Revenues from Contracts with _2
Revenues from Contracts with Customers (Tables) | 3 Months Ended |
Apr. 01, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Schedule of disaggregated revenues | Disaggregated revenues by customer-type were as follows: Three Months Ended April 1, 2022 Defense Solutions Civil Health Total (in millions) DoD and U.S. Intelligence Community $ 1,539 $ 20 $ 238 $ 1,797 Other government agencies (1) 222 613 385 1,220 Commercial and non-U.S. customers 287 147 27 461 Total $ 2,048 $ 780 $ 650 $ 3,478 Three Months Ended April 2, 2021 Defense Solutions Civil Health Total (in millions) DoD and U.S. Intelligence Community $ 1,407 $ 13 $ 158 $ 1,578 Other government agencies (1) 272 605 407 1,284 Commercial and non-U.S. customers 278 125 26 429 Total $ 1,957 $ 743 $ 591 $ 3,291 (1) Includes federal government agencies other than the DoD and U.S. Intelligence Community, as well as state and local government agencies. Disaggregated revenues by contract-type were as follows: Three Months Ended April 1, 2022 Defense Solutions Civil Health Total (in millions) Cost-reimbursement and fixed-price-incentive-fee $ 1,183 $ 408 $ 167 $ 1,758 Firm-fixed-price 618 255 417 1,290 Time-and-materials and fixed-price-level-of-effort 247 117 66 430 Total $ 2,048 $ 780 $ 650 $ 3,478 Three Months Ended April 2, 2021 Defense Solutions Civil Health Total (in millions) Cost-reimbursement and fixed-price-incentive-fee $ 1,163 $ 374 $ 99 $ 1,636 Firm-fixed-price 553 262 392 1,207 Time-and-materials and fixed-price-level-of-effort 241 107 100 448 Total $ 1,957 $ 743 $ 591 $ 3,291 Disaggregated revenues by geographic location were as follows: Three Months Ended April 1, 2022 Defense Solutions Civil Health Total (in millions) United States $ 1,810 $ 741 $ 650 $ 3,201 International 238 39 — 277 Total $ 2,048 $ 780 $ 650 $ 3,478 Three Months Ended April 2, 2021 Defense Solutions Civil Health Total (in millions) United States $ 1,713 $ 704 $ 591 $ 3,008 International 244 39 — 283 Total $ 1,957 $ 743 $ 591 $ 3,291 |
Components of contract assets and contract liabilities | The components of contract assets and contract liabilities consisted of the following: Balance sheet line item April 1, December 31, (in millions) Contract assets - current: Unbilled receivables Receivables, net $ 1,078 $ 1,022 Contract liabilities - current: Deferred revenue (1) Accounts payable and accrued liabilities $ 382 $ 364 Contract liabilities - non-current: Deferred revenue (1) Other long-term liabilities $ 25 $ 24 (1) Certain contracts record revenue net of cost of revenues, and therefore, the respective deferred revenue balance will not fully convert to revenue. |
Acquisitions, Divestitures, G_2
Acquisitions, Divestitures, Goodwill and Intangible Assets (Tables) | 3 Months Ended |
Apr. 01, 2022 | |
Business Combinations [Abstract] | |
Schedule of preliminary fair values of intangible assets acquired and related weighted average amortization periods | The following table summarizes the fair value of intangible assets acquired at the Purchase Date and the related weighted average amortization period: Weighted average amortization period Fair value (in years) (in millions) Programs 12 $ 89 |
Schedule of carrying amount of goodwill by reportable segment | The following table presents changes in the carrying amount of goodwill by reportable segment: Defense Solutions Civil Health Total (in millions) Goodwill at January 1, 2021 $ 3,300 $ 2,047 $ 966 $ 6,313 Acquisitions of businesses 425 5 — 430 Divestiture of a business (1) — — (1) Goodwill re-allocation (17) 17 — — Foreign currency translation adjustments (26) 28 — 2 Goodwill at December 31, 2021 $ 3,681 $ 2,097 $ 966 $ 6,744 Acquisition of a business 1 — — 1 Divestiture of a business (4) — — (4) Foreign currency translation adjustments 8 (7) — 1 Goodwill at April 1, 2022 $ 3,686 $ 2,090 $ 966 $ 6,742 |
Schedule of intangible assets | Intangible assets, net consisted of the following: April 1, 2022 December 31, 2021 Gross carrying value Accumulated amortization Net carrying value Gross carrying value Accumulated amortization Net carrying value (in millions) Finite-lived intangible assets: Programs $ 1,701 $ (866) $ 835 $ 1,722 $ (830) $ 892 Software and technology 230 (127) 103 230 (121) 109 Customer relationships 91 (16) 75 97 (18) 79 Backlog 6 (6) — 38 (37) 1 Trade names 1 (1) — 1 (1) — Total finite-lived intangible assets 2,029 (1,016) 1,013 2,088 (1,007) 1,081 Indefinite-lived intangible assets: In-process research and development 92 — 92 92 — 92 Trade names 4 — 4 4 — 4 Total indefinite-lived intangible assets 96 — 96 96 — 96 Total intangible assets $ 2,125 $ (1,016) $ 1,109 $ 2,184 $ (1,007) $ 1,177 |
Schedule of estimated annual amortization expense | The estimated annual amortization expense as of April 1, 2022, was as follows: Fiscal year ending (in millions) 2022 (remainder of year) $ 173 2023 203 2024 150 2025 120 2026 96 2027 and thereafter 271 $ 1,013 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 3 Months Ended |
Apr. 01, 2022 | |
Fair Value Disclosures [Abstract] | |
Schedule of financial assets measured on a recurring basis | The financial instruments measured at fair value on a recurring basis primarily consisted of the following: April 1, 2022 December 31, 2021 Carrying value Fair value Carrying value Fair value (in millions) Financial liabilities: Derivatives $ 13 $ 13 $ 53 $ 53 |
Derivative Instruments (Tables)
Derivative Instruments (Tables) | 3 Months Ended |
Apr. 01, 2022 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Schedule of fair value of the company's interest rate swaps | The fair value of the interest rate swaps was as follows: Liability derivatives Balance sheet line item April 1, December 31, (in millions) Cash flow interest rate swaps Other long-term liabilities $ 13 $ 53 |
Schedule of effect of the company's cash flow hedges on other comprehensive income and earnings | The effect of the cash flow hedges on other comprehensive income (loss) and earnings for the periods presented was as follows: Three Months Ended April 1, April 2, (in millions) Total interest expense, net presented in the condensed consolidated statements of income in which the effects of cash flow hedges are recorded $ 48 $ 45 Amount recognized in other comprehensive income $ 32 $ 12 Amount reclassified from accumulated other comprehensive income (loss) to interest expense, net $ 6 $ 5 |
Debt (Tables)
Debt (Tables) | 3 Months Ended |
Apr. 01, 2022 | |
Debt Disclosure [Abstract] | |
Schedule of company's debt | Our debt consisted of the following: Stated interest rate Effective interest rate April 1, 2022 (1) December 31, 2021 (1) (in millions) Short-term debt: Commercial paper 0.52%-1.13% Various $ 75 $ — Senior unsecured term loans: $380 million term loan, due May 2022 1.59% 1.69% 380 380 Total short-term debt $ 455 $ 380 Long-term debt: Senior unsecured term loans: $1,925 million term loan, due January 2025 1.84% 2.11% $ 1,275 $ 1,298 Senior unsecured notes: $500 million notes, due May 2023 2.95% 3.17% 499 498 $500 million notes, due May 2025 3.63% 3.76% 497 497 $750 million notes due May 2030 4.38% 4.50% 738 738 $1,000 million notes, due February 2031 2.30% 2.38% 990 990 $250 million notes, due July 2032 7.13% 7.43% 247 247 $300 million notes, due July 2033 5.50% 5.88% 158 158 $300 million notes, due December 2040 5.95% 6.03% 216 216 Notes payable and finance leases due on various dates through fiscal 2032 1.56%-4.18% Various 50 54 Total long-term debt 4,670 4,696 Less current portion (101) (103) Total long-term debt, net of current portion $ 4,569 $ 4,593 (1) The carrying amounts of the senior unsecured term loans and notes as of April 1, 2022, and December 31, 2021, include the remaining principal outstanding of $5,041 million and $5,065 million, respectively, less total unamortized debt discounts and deferred debt issuances costs of $41 million and $43 million, respectively. |
Accumulated Other Comprehensi_2
Accumulated Other Comprehensive Income (Loss) (Tables) | 3 Months Ended |
Apr. 01, 2022 | |
Equity [Abstract] | |
Schedule of changes in the components of accumulated other comprehensive (loss) income | Changes in the components of accumulated other comprehensive income (loss) were as follows: Foreign currency translation adjustments Unrecognized gain (loss) on derivative instruments Pension adjustments Total accumulated other comprehensive income (loss) (in millions) Balance at January 1, 2021 $ 30 $ (70) $ (6) $ (46) Other comprehensive income (loss) (3) 18 17 32 Taxes (5) (8) (4) (17) Reclassification from accumulated other comprehensive income (loss) — 19 — 19 Balance at December 31, 2021 22 (41) 7 (12) Other comprehensive income (loss) (2) 32 1 31 Taxes 4 (9) — (5) Reclassification from accumulated other comprehensive income (loss) — 6 — 6 Balance at April 1, 2022 $ 24 $ (12) $ 8 $ 20 |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 3 Months Ended |
Apr. 01, 2022 | |
Earnings Per Share [Abstract] | |
Reconciliation of the weighted average number of shares outstanding used to compute basic and diluted EPS | The following table provides a reconciliation of the weighted average number of shares outstanding used to compute basic and diluted EPS for the periods presented: Three Months Ended April 1, April 2, (in millions) Basic weighted average number of shares outstanding 139 142 Dilutive common share equivalents—stock options and other stock awards 1 2 Diluted weighted average number of shares outstanding 140 144 |
Sale of Accounts Receivable (Ta
Sale of Accounts Receivable (Tables) | 3 Months Ended |
Apr. 01, 2022 | |
Receivables [Abstract] | |
Accounts receivable sale activity | Sold receivables activity for the periods presented was as follows: Three Months Ended April 1, April 2, (in millions) Sales of accounts receivable $ 209 $ 465 Cash collections on sold receivables remitted to financial institution (209) (371) Outstanding balance sold to financial institution — 94 Cash collected but not yet remitted to financial institution — (19) Sold receivables due from customers $ — $ 75 |
Business Segments (Tables)
Business Segments (Tables) | 3 Months Ended |
Apr. 01, 2022 | |
Segment Reporting [Abstract] | |
Schedule of segment reporting information by segment | The segment information for the periods presented was as follows: Three Months Ended April 1, April 2, (in millions) Revenues: Defense Solutions $ 2,049 $ 1,958 Civil 795 766 Health 650 591 Total revenues $ 3,494 $ 3,315 Operating income (loss): Defense Solutions $ 133 $ 152 Civil 43 74 Health 118 102 Corporate (23) (20) Total operating income $ 271 $ 308 |
Commitment and Contingencies (T
Commitment and Contingencies (Tables) | 3 Months Ended |
Apr. 01, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Guaranteed obligation, fiscal year maturity | As of April 1, 2022, the future expirations of the outstanding letters of credit and surety bonds were as follows: Fiscal year ending (in millions) 2022 (remainder of year) $ 38 2023 11 2024 81 2025 5 2026 2 2027 and thereafter 14 $ 151 |
Basis of Presentation and Sum_4
Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details) $ in Millions | 3 Months Ended | ||
Apr. 01, 2022USD ($)segment | Apr. 02, 2021USD ($) | Dec. 31, 2021USD ($) | |
Significant Accounting Policies [Line Items] | |||
Number of reportable segments | segment | 3 | ||
Revenue recognized for performance obligation satisfied in the previous periods | $ 14 | $ 9 | |
Accounts payable and accrued liabilities | 2,214 | $ 2,141 | |
Restricted cash balances | 131 | 148 | |
Cash and Cash Equivalents | |||
Significant Accounting Policies [Line Items] | |||
Accounts payable and accrued liabilities | $ 176 | $ 138 |
Basis of Presentation and Sum_5
Basis of Presentation and Summary of Significant Accounting Policies (Changes in Estimates on Contracts) (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | |
Apr. 01, 2022 | Apr. 02, 2021 | |
Accounting Policies [Abstract] | ||
Favorable impact | $ 41 | $ 31 |
Unfavorable impact | (26) | (19) |
Net impact to income before income taxes | $ 15 | $ 12 |
Impact on diluted EPS attributable to Leidos common stockholders (dollars per share) | $ 0.08 | $ 0.06 |
Revenues from Contracts with _3
Revenues from Contracts with Customers (Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | |
Apr. 01, 2022 | Apr. 02, 2021 | |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Remaining performance obligations, which are expected to be recognized as revenue | $ 15,400 | |
Revenue recognized under ASC 842 | 16 | $ 24 |
Contract liability revenue recognized | $ 188 | $ 144 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01 | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Remaining performance obligations, which are expected to be recognized as revenue, period (in months) | 12 months | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01 | Performance Period One | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Remaining performance obligations, which are expected to be recognized as revenue (as percent) | 55.00% | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01 | Performance Period Two | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Remaining performance obligations, which are expected to be recognized as revenue (as percent) | 73.00% | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01 | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Remaining performance obligations, which are expected to be recognized as revenue, period (in months) | 24 months |
Revenues from Contracts with _4
Revenues from Contracts with Customers (Disaggregation of revenue) (Details) - USD ($) $ in Millions | 3 Months Ended | |
Apr. 01, 2022 | Apr. 02, 2021 | |
Disaggregation of Revenue [Line Items] | ||
Revenues | $ 3,478 | $ 3,291 |
United States | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 3,201 | 3,008 |
International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 277 | 283 |
Cost-reimbursement and fixed-price-incentive-fee | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 1,758 | 1,636 |
Firm-fixed-price | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 1,290 | 1,207 |
Time-and-materials and fixed-price-level-of-effort | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 430 | 448 |
DoD and U.S. Intelligence Community | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 1,797 | 1,578 |
Other government agencies | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 1,220 | 1,284 |
Commercial and non-U.S. customers | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 461 | 429 |
Defense Solutions | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 2,048 | 1,957 |
Defense Solutions | United States | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 1,810 | 1,713 |
Defense Solutions | International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 238 | 244 |
Defense Solutions | Cost-reimbursement and fixed-price-incentive-fee | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 1,183 | 1,163 |
Defense Solutions | Firm-fixed-price | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 618 | 553 |
Defense Solutions | Time-and-materials and fixed-price-level-of-effort | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 247 | 241 |
Defense Solutions | DoD and U.S. Intelligence Community | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 1,539 | 1,407 |
Defense Solutions | Other government agencies | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 222 | 272 |
Defense Solutions | Commercial and non-U.S. customers | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 287 | 278 |
Civil | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 780 | 743 |
Civil | United States | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 741 | 704 |
Civil | International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 39 | 39 |
Civil | Cost-reimbursement and fixed-price-incentive-fee | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 408 | 374 |
Civil | Firm-fixed-price | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 255 | 262 |
Civil | Time-and-materials and fixed-price-level-of-effort | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 117 | 107 |
Civil | DoD and U.S. Intelligence Community | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 20 | 13 |
Civil | Other government agencies | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 613 | 605 |
Civil | Commercial and non-U.S. customers | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 147 | 125 |
Health | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 650 | 591 |
Health | United States | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 650 | 591 |
Health | International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 0 | 0 |
Health | Cost-reimbursement and fixed-price-incentive-fee | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 167 | 99 |
Health | Firm-fixed-price | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 417 | 392 |
Health | Time-and-materials and fixed-price-level-of-effort | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 66 | 100 |
Health | DoD and U.S. Intelligence Community | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 238 | 158 |
Health | Other government agencies | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 385 | 407 |
Health | Commercial and non-U.S. customers | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | $ 27 | $ 26 |
Revenues from Contracts with _5
Revenues from Contracts with Customers (Contract Asset and Liabilities) (Details) - USD ($) $ in Millions | Apr. 01, 2022 | Dec. 31, 2021 |
Revenue from Contract with Customer [Abstract] | ||
Contract assets - current: | $ 1,078 | $ 1,022 |
Contract liabilities - current: | 382 | 364 |
Contract liabilities - non-current: | $ 25 | $ 24 |
Acquisitions, Divestitures, G_3
Acquisitions, Divestitures, Goodwill and Intangible Assets (Narrative) (Details) - USD ($) | Sep. 21, 2021 | May 07, 2021 | Apr. 01, 2022 | Apr. 02, 2021 | Apr. 29, 2022 | Dec. 31, 2021 | Jan. 01, 2021 |
Restructuring Cost and Reserve [Line Items] | |||||||
Goodwill | $ 6,742,000,000 | $ 6,744,000,000 | $ 6,313,000,000 | ||||
Goodwill impairments | 0 | $ 0 | |||||
Amortization expense | 59,000,000 | $ 55,000,000 | |||||
Civil | |||||||
Restructuring Cost and Reserve [Line Items] | |||||||
Goodwill | 2,090,000,000 | $ 2,097,000,000 | $ 2,047,000,000 | ||||
Reporting unit, percentage of fair value in excess of carrying amount | 6.00% | ||||||
Subsequent Event | Disposal Group, Held-for-sale, Not Discontinued Operations | Aviation & Missile Solutions LLC | |||||||
Restructuring Cost and Reserve [Line Items] | |||||||
Sale price of business disposal | $ 15,000,000 | ||||||
Gibbs & Cox | |||||||
Restructuring Cost and Reserve [Line Items] | |||||||
Preliminary purchase consideration | $ 375,000,000 | ||||||
Cash acquired | $ 1,000,000 | ||||||
Goodwill | 276,000,000 | ||||||
Revenue | $ 27,000,000 | ||||||
Series of Individually Immaterial Business Acquisitions | |||||||
Restructuring Cost and Reserve [Line Items] | |||||||
Preliminary purchase consideration | $ 36,000,000 | ||||||
Goodwill | 25,000,000 | ||||||
Intangible assets | $ 8,000,000 |
Acquisitions, Divestitures, G_4
Acquisitions, Divestitures, Goodwill and Intangible Assets (Schedule of intangible assets acquired) (Details) - Gibbs & Cox - Programs $ in Millions | May 07, 2021USD ($) |
Acquired Indefinite-lived Intangible Assets [Line Items] | |
Weighted average amortization period | 12 years |
Finite-lived intangible assets | $ 89 |
Acquisitions, Divestitures, G_5
Acquisitions, Divestitures, Goodwill and Intangible Assets (Schedule of Changes in Goodwill by Segment) (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended |
Apr. 01, 2022 | Dec. 31, 2021 | |
Goodwill [Roll Forward] | ||
Goodwill, Beginning Balance | $ 6,744 | $ 6,313 |
Acquisitions of businesses | 1 | 430 |
Divestiture of a business | (4) | (1) |
Goodwill re-allocation | 0 | |
Foreign currency translation adjustments | 1 | 2 |
Ending balance, Goodwill | 6,742 | 6,744 |
Defense Solutions | ||
Goodwill [Roll Forward] | ||
Goodwill, Beginning Balance | 3,681 | 3,300 |
Acquisitions of businesses | 1 | 425 |
Divestiture of a business | (4) | (1) |
Goodwill re-allocation | (17) | |
Foreign currency translation adjustments | 8 | (26) |
Ending balance, Goodwill | 3,686 | 3,681 |
Civil | ||
Goodwill [Roll Forward] | ||
Goodwill, Beginning Balance | 2,097 | 2,047 |
Acquisitions of businesses | 0 | 5 |
Divestiture of a business | 0 | 0 |
Goodwill re-allocation | 17 | |
Foreign currency translation adjustments | (7) | 28 |
Ending balance, Goodwill | 2,090 | 2,097 |
Health | ||
Goodwill [Roll Forward] | ||
Goodwill, Beginning Balance | 966 | 966 |
Acquisitions of businesses | 0 | 0 |
Divestiture of a business | 0 | 0 |
Goodwill re-allocation | 0 | |
Foreign currency translation adjustments | 0 | 0 |
Ending balance, Goodwill | $ 966 | $ 966 |
Acquisitions, Divestitures, G_6
Acquisitions, Divestitures, Goodwill and Intangible Assets (Schedule of intangible assets) (Details) - USD ($) $ in Millions | Apr. 01, 2022 | Dec. 31, 2021 |
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived intangible assets, gross carrying value | $ 2,029 | $ 2,088 |
Finite-lived intangible assets, accumulated amortization | (1,016) | (1,007) |
Finite-lived intangible assets, net carrying value | 1,013 | 1,081 |
Indefinite-lived intangible assets | 96 | 96 |
Total intangible assets, gross carrying value | 2,125 | 2,184 |
Total intangible assets, net carrying value | 1,109 | 1,177 |
In-process research and development | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Indefinite-lived intangible assets | 92 | 92 |
Trade names | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Indefinite-lived intangible assets | 4 | 4 |
Programs | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived intangible assets, gross carrying value | 1,701 | 1,722 |
Finite-lived intangible assets, accumulated amortization | (866) | (830) |
Finite-lived intangible assets, net carrying value | 835 | 892 |
Software and technology | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived intangible assets, gross carrying value | 230 | 230 |
Finite-lived intangible assets, accumulated amortization | (127) | (121) |
Finite-lived intangible assets, net carrying value | 103 | 109 |
Customer relationships | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived intangible assets, gross carrying value | 91 | 97 |
Finite-lived intangible assets, accumulated amortization | (16) | (18) |
Finite-lived intangible assets, net carrying value | 75 | 79 |
Backlog | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived intangible assets, gross carrying value | 6 | 38 |
Finite-lived intangible assets, accumulated amortization | (6) | (37) |
Finite-lived intangible assets, net carrying value | 0 | 1 |
Trade names | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived intangible assets, gross carrying value | 1 | 1 |
Finite-lived intangible assets, accumulated amortization | (1) | (1) |
Finite-lived intangible assets, net carrying value | $ 0 | $ 0 |
Acquisitions, Divestitures, G_7
Acquisitions, Divestitures, Goodwill and Intangible Assets (Schedule of estimated annual amortization expense) (Details) - USD ($) $ in Millions | Apr. 01, 2022 | Dec. 31, 2021 |
Estimated Annual Intangible Amortization Expense | ||
2022 (remainder of year) | $ 173 | |
2023 | 203 | |
2024 | 150 | |
2025 | 120 | |
2026 | 96 | |
2027 and thereafter | 271 | |
Finite-lived intangible assets, net carrying value | $ 1,013 | $ 1,081 |
Fair Value Measurements (Financ
Fair Value Measurements (Financial Instruments Measured at Fair Value on Recurring Basis) (Details) - USD ($) $ in Millions | Apr. 01, 2022 | Dec. 31, 2021 |
Carrying value | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Derivative liability | $ 13 | $ 53 |
Fair value | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Derivative liability | $ 13 | $ 53 |
Fair Value Measurements (Narrat
Fair Value Measurements (Narrative) (Details) - USD ($) $ in Billions | Apr. 01, 2022 | Dec. 31, 2021 |
Fair value | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair value of debt instrument | $ 5.1 | $ 5.4 |
Carrying value | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair value of debt instrument | 5.1 | $ 5.1 |
Designated as Hedging Instrument | Interest Rate Swaps | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Hedged instrument, face amount | $ 1 |
Derivative Instruments (Interes
Derivative Instruments (Interest rate swaps) (Details) - USD ($) $ in Millions | Apr. 01, 2022 | Dec. 31, 2021 |
Cash Flow Hedging | Interest Rate Swaps | Other long-term liabilities | Designated as Hedging Instrument | ||
Derivative [Line Items] | ||
Liability derivatives | $ 13 | $ 53 |
Derivative Instruments (Narrati
Derivative Instruments (Narrative) (Details) $ in Millions | Apr. 01, 2022USD ($) |
Derivative [Line Items] | |
Gains expected to be reclassified in the next 12 months | $ 15 |
Designated as Hedging Instrument | Interest Rate Swaps | |
Derivative [Line Items] | |
Hedged instrument, face amount | $ 1,000 |
Designated as Hedging Instrument | Interest Rate Swap, Maturity Date August 2025 | Unsecured Debt | |
Derivative [Line Items] | |
Stated interest rate (in percentage) | 3.00% |
Derivative Instruments (Effect
Derivative Instruments (Effect of Cash Flow Hedge) (Details) - USD ($) $ in Millions | 3 Months Ended | |
Apr. 01, 2022 | Apr. 02, 2021 | |
Derivatives, Fair Value [Line Items] | ||
Total interest expense, net presented in the condensed consolidated statements of income in which the effects of cash flow hedges are recorded | $ 48 | $ 45 |
Amount recognized in other comprehensive income | 32 | 12 |
Interest Expense | ||
Derivatives, Fair Value [Line Items] | ||
Amount reclassified from accumulated other comprehensive income (loss) to interest expense, net | $ 6 | $ 5 |
Debt (Summary of debt) (Details
Debt (Summary of debt) (Details) - USD ($) | Apr. 01, 2022 | Dec. 31, 2021 |
Debt Instrument [Line Items] | ||
Commercial Paper | $ 75,000,000 | $ 0 |
Total short-term debt | 455,000,000 | 380,000,000 |
Total long-term debt | 4,670,000,000 | 4,696,000,000 |
Less current portion | (101,000,000) | (103,000,000) |
Total long-term debt, net of current portion | 4,569,000,000 | 4,593,000,000 |
Long-term debt | 5,041,000,000 | 5,065,000,000 |
Unamortized debt discounts and deferred debt issuances costs | 41,000,000 | 43,000,000 |
Unsecured Debt | $1,925 million term loan, due January 2025 | ||
Debt Instrument [Line Items] | ||
Debt instrument, face amount | $ 1,925,000,000 | |
Stated interest rate | 1.84% | |
Effective interest rate | 2.11% | |
Senior unsecured debt | $ 1,275,000,000 | 1,298,000,000 |
Unsecured Debt | $500 million notes, due May 2023 | ||
Debt Instrument [Line Items] | ||
Debt instrument, face amount | $ 500,000,000 | |
Stated interest rate | 2.95% | |
Effective interest rate | 3.17% | |
Senior unsecured debt | $ 499,000,000 | 498,000,000 |
Unsecured Debt | $500 million notes, due May 2025 | ||
Debt Instrument [Line Items] | ||
Debt instrument, face amount | $ 500,000,000 | |
Stated interest rate | 3.63% | |
Effective interest rate | 3.76% | |
Senior unsecured debt | $ 497,000,000 | 497,000,000 |
Unsecured Debt | $750 million notes due May 2030 | ||
Debt Instrument [Line Items] | ||
Debt instrument, face amount | $ 750,000,000 | |
Stated interest rate | 4.38% | |
Effective interest rate | 4.50% | |
Senior unsecured debt | $ 738,000,000 | 738,000,000 |
Unsecured Debt | $1,000 million notes, due February 2031 | ||
Debt Instrument [Line Items] | ||
Debt instrument, face amount | $ 1,000,000,000 | |
Stated interest rate | 2.30% | |
Effective interest rate | 2.38% | |
Senior unsecured debt | $ 990,000,000 | 990,000,000 |
Unsecured Debt | $250 million notes, due July 2032 | ||
Debt Instrument [Line Items] | ||
Debt instrument, face amount | $ 250,000,000 | |
Stated interest rate | 7.13% | |
Effective interest rate | 7.43% | |
Senior unsecured debt | $ 247,000,000 | 247,000,000 |
Unsecured Debt | $300 million notes, due July 2033 | ||
Debt Instrument [Line Items] | ||
Debt instrument, face amount | $ 300,000,000 | |
Stated interest rate | 5.50% | |
Effective interest rate | 5.88% | |
Senior unsecured debt | $ 158,000,000 | 158,000,000 |
Unsecured Debt | $300 million notes, due December 2040 | ||
Debt Instrument [Line Items] | ||
Debt instrument, face amount | $ 300,000,000 | |
Stated interest rate | 5.95% | |
Effective interest rate | 6.03% | |
Senior unsecured debt | $ 216,000,000 | 216,000,000 |
Unsecured Debt | Notes payable and finance leases due on various dates through fiscal 2032 | ||
Debt Instrument [Line Items] | ||
Notes payable and finance leases due on various dates through fiscal 2032 | $ 50,000,000 | 54,000,000 |
Unsecured Debt | Notes payable and finance leases due on various dates through fiscal 2032 | Minimum | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 1.56% | |
Unsecured Debt | Notes payable and finance leases due on various dates through fiscal 2032 | Maximum | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 4.18% | |
Unsecured Debt | Minimum | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 0.52% | |
Unsecured Debt | Maximum | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 1.13% | |
Unsecured Debt | $380 million term loan, due May 2022 | ||
Debt Instrument [Line Items] | ||
Debt instrument, face amount | $ 380,000,000 | |
Stated interest rate | 1.59% | |
Effective interest rate | 1.69% | |
Senior unsecured debt | $ 380,000,000 | $ 380,000,000 |
Debt (Narrative) (Details)
Debt (Narrative) (Details) | May 07, 2021USD ($) | Apr. 01, 2022USD ($)increaseextension | Apr. 02, 2021USD ($) | Dec. 31, 2021USD ($) |
Debt Instrument [Line Items] | ||||
Commercial paper outstanding | $ 75,000,000 | $ 0 | ||
Payments of long-term debt | 27,000,000 | $ 26,000,000 | ||
Amortization of debt discount and debt issuance costs | $ 3,000,000 | 2,000,000 | ||
Commercial Paper | ||||
Debt Instrument [Line Items] | ||||
Debt instrument term | 397 days | |||
Commercial paper | $ 750,000,000 | |||
Minimum denominations of commercial paper | 250,000 | |||
Unsecured Debt | ||||
Debt Instrument [Line Items] | ||||
Repayment of debt principal | 24,000,000 | 24,000,000 | ||
Line of Credit | Revolving Credit Facility | ||||
Debt Instrument [Line Items] | ||||
Long-term line of credit | $ 0 | $ 0 | ||
Term Loan | Unsecured Debt | ||||
Debt Instrument [Line Items] | ||||
Debt instrument, face amount | $ 380,000,000 | |||
Debt instrument term | 364 days | |||
The Credit Agreement | ||||
Debt Instrument [Line Items] | ||||
Number of additional extensions | extension | 2 | |||
Debt instrument, extension term (in years) | 1 year | |||
Covenant, adjusted consolidated total debt to consolidated EBITDA ratio | 3.75 | |||
Number of potential leverage ratio increases | increase | 2 | |||
Covenant, leverage ratio, maximum, potential increase following material acquisition | 4.50 | |||
Covenant, consolidated EBITDA to interest expense ratio | 3.50 | |||
The Credit Agreement | London Interbank Offered Rate (LIBOR) | ||||
Debt Instrument [Line Items] | ||||
Variable rate percentage | 1.38% | |||
The Credit Agreement | London Interbank Offered Rate (LIBOR) | Minimum | ||||
Debt Instrument [Line Items] | ||||
Variable rate percentage | 1.13% | |||
The Credit Agreement | London Interbank Offered Rate (LIBOR) | Maximum | ||||
Debt Instrument [Line Items] | ||||
Variable rate percentage | 1.75% | |||
The Credit Agreement | Unsecured Debt | Term Loan | ||||
Debt Instrument [Line Items] | ||||
Debt instrument, face amount | $ 1,900,000,000 | |||
The Credit Agreement | Line of Credit | Revolving Credit Facility | ||||
Debt Instrument [Line Items] | ||||
Unsecured borrowing capacity | 750,000,000 | |||
Debt Payments, Excluding Refinanced Debt | ||||
Debt Instrument [Line Items] | ||||
Payments of long-term debt | $ 27,000,000 | $ 26,000,000 | ||
2021 Credit Agreement | ||||
Debt Instrument [Line Items] | ||||
Covenant, adjusted consolidated total debt to consolidated EBITDA ratio | 3.75 | |||
Covenant, leverage ratio, maximum, potential increase following material acquisition | 4.50 | |||
Covenant, consolidated EBITDA to interest expense ratio | 3.50 | |||
2021 Credit Agreement | Unsecured Debt | London Interbank Offered Rate (LIBOR) | ||||
Debt Instrument [Line Items] | ||||
Variable rate percentage | 1.13% | |||
2021 Credit Agreement | Unsecured Debt | Base Rate | ||||
Debt Instrument [Line Items] | ||||
Variable rate percentage | 0.13% |
Accumulated Other Comprehensi_3
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended |
Apr. 01, 2022 | Dec. 31, 2021 | |
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||
Beginning Balance | $ 4,344 | $ 3,871 |
Ending Balance | 4,008 | 4,344 |
Accumulated other comprehensive income | ||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||
Beginning Balance | (12) | (46) |
Other comprehensive income (loss) | 31 | 32 |
Taxes | (5) | (17) |
Reclassification from accumulated other comprehensive income (loss) | 6 | 19 |
Ending Balance | 20 | (12) |
Foreign currency translation adjustments | ||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||
Beginning Balance | 22 | 30 |
Other comprehensive income (loss) | (2) | (3) |
Taxes | 4 | (5) |
Reclassification from accumulated other comprehensive income (loss) | 0 | 0 |
Ending Balance | 24 | 22 |
Unrecognized gain (loss) on derivative instruments | ||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||
Beginning Balance | (41) | (70) |
Other comprehensive income (loss) | 32 | 18 |
Taxes | (9) | (8) |
Reclassification from accumulated other comprehensive income (loss) | 6 | 19 |
Ending Balance | (12) | (41) |
Pension adjustments | ||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||
Beginning Balance | 7 | (6) |
Other comprehensive income (loss) | 1 | 17 |
Taxes | 0 | (4) |
Reclassification from accumulated other comprehensive income (loss) | 0 | 0 |
Ending Balance | $ 8 | $ 7 |
Earnings Per Share (Reconciliat
Earnings Per Share (Reconciliation of weighted average number of shares outstanding) (Details) - shares shares in Millions | 3 Months Ended | |
Apr. 01, 2022 | Apr. 02, 2021 | |
Earnings Per Share [Abstract] | ||
Basic weighted average number of shares outstanding (in shares) | 139 | 142 |
Dilutive common share equivalents-stock options and other stock awards (in shares) | 1 | 2 |
Diluted weighted average number of shares outstanding (shares) | 140 | 144 |
Earnings Per Share (Narrative)
Earnings Per Share (Narrative) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | Feb. 16, 2022 | Apr. 01, 2022 | Apr. 02, 2021 |
Equity, Class of Treasury Stock [Line Items] | |||
Anti-dilutive shares (in shares) | 1 | 1 | |
Accelerated Share Repurchase | |||
Equity, Class of Treasury Stock [Line Items] | |||
Payments for repurchase of common stock | $ 500 | ||
Number of shares repurchased and retired (in shares) | 4.5 | ||
Accelerated share repurchases, initial price paid per share (dollars per share) | $ 88.72 |
Sale of Accounts Receivable (Na
Sale of Accounts Receivable (Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | |
Apr. 01, 2022 | Apr. 02, 2021 | |
Receivables [Abstract] | ||
Receivable collectible period | 30 days | |
Sales of accounts receivable | $ 209 | $ 465 |
Proceeds from sale of receivables | $ 209 | $ 464 |
Sale of Accounts Receivable (Ac
Sale of Accounts Receivable (Accounts Receivable Sale Activity) (Details) - USD ($) $ in Millions | 3 Months Ended | |
Apr. 01, 2022 | Apr. 02, 2021 | |
Receivables [Abstract] | ||
Sales of accounts receivable | $ 209 | $ 465 |
Cash collections on sold receivables remitted to financial institution | (209) | (371) |
Outstanding balance sold to financial institution | 0 | 94 |
Cash collected but not yet remitted to financial institution | 0 | (19) |
Sold receivables due from customers | $ 0 | $ 75 |
Business Segments (Schedule of
Business Segments (Schedule of segment reporting information by segment) (Details) - USD ($) $ in Millions | 3 Months Ended | |
Apr. 01, 2022 | Apr. 02, 2021 | |
Segment Reporting Information [Line Items] | ||
Revenues | $ 3,494 | $ 3,315 |
Operating income (loss) | 271 | 308 |
Corporate | ||
Segment Reporting Information [Line Items] | ||
Operating income (loss) | (23) | (20) |
Defense Solutions | ||
Segment Reporting Information [Line Items] | ||
Revenues | 2,049 | 1,958 |
Defense Solutions | Operating Segments | ||
Segment Reporting Information [Line Items] | ||
Operating income (loss) | 133 | 152 |
Civil | ||
Segment Reporting Information [Line Items] | ||
Revenues | 795 | 766 |
Civil | Operating Segments | ||
Segment Reporting Information [Line Items] | ||
Operating income (loss) | 43 | 74 |
Health | ||
Segment Reporting Information [Line Items] | ||
Revenues | 650 | 591 |
Health | Operating Segments | ||
Segment Reporting Information [Line Items] | ||
Operating income (loss) | $ 118 | $ 102 |
Commitments and Contingencies (
Commitments and Contingencies (Narrative) (Details) | Oct. 30, 2020USD ($) | Nov. 22, 2019patent | Aug. 30, 2018USD ($) | Apr. 10, 2018USD ($) | Jan. 31, 2021USD ($) | Apr. 01, 2022USD ($) |
Standby Letters of Credit | ||||||
Legal Proceedings [Line Items] | ||||||
Amount outstanding | $ 51,000,000 | |||||
Performance Guarantee | ||||||
Legal Proceedings [Line Items] | ||||||
Surety bonds notional amount | $ 100,000,000 | |||||
Virnet X Inc | ||||||
Legal Proceedings [Line Items] | ||||||
Amount awarded from other party | $ 503,000,000 | $ 595,000,000 | $ 502,000,000 | |||
Royalty rate awarded (per device) | $ 0.84 | 1.20 | ||||
Awarded to the other party, interest and legal fees | $ 93,000,000 | |||||
Number of infringed patents | patent | 2 | |||||
Number of infringed other patents | patent | 2 | |||||
Additional costs and interest | $ 75,000,000 | |||||
Leidos | ||||||
Legal Proceedings [Line Items] | ||||||
Litigation settlement, percentage of total (percentage) | 25.00% |
Commitments and Contingencies_2
Commitments and Contingencies (Future Expirations Maturity Table) (Details) - Standby Letters of Credit and Surety Bonds $ in Millions | Apr. 01, 2022USD ($) |
Guaranteed Obligation, Type [Line Items] | |
2022 (remainder of year) | $ 38 |
2023 | 11 |
2024 | 81 |
2025 | 5 |
2026 | 2 |
2027 and thereafter | 14 |
Guaranteed obligation | $ 151 |